HZ-Q1070 / HealZen Therap - LARVOL DELTA

Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies (ASH 2024) - "The preliminary data from the FIH phase I study of HZ-Q1070 in R/R BCM demonstrated a safety profile and response signal. This trial is currently ongoing."

First-in-human • P1 data • Preclinical • Chronic Lymphocytic Leukemia • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Targeted Protein Degradation • BTK • IKZF1